Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicyluric Acid SCHEMBL29935452 | 1.00 | HPGD (0.58) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL4952951 | 0.89 | LMNA (0.63) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL31448014 | 0.88 | KEAP1 (0.62) | HTTMAPTTSHRKDM4EGAA | |
| SCHEMBL3677100 | 0.87 | ALOX5 (0.64) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL29387023 | 0.87 | ALOX5 (0.64) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL14839314 | 0.85 | HPGD (0.55) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL7325670 | 0.84 | KDM4E (0.61) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL23014512 | 0.84 | HPGD (0.54) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL12562532 | 0.83 | NAAA (0.57) | HPGDHTTHSD17B10NPC1ALDH1A1 | |
| SCHEMBL3082099 | 0.83 | CA1 (0.56) | HPGDHTTHSD17B10NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 810 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-3383177-B1 | COMPOSITION FOR CROP CARE AND PROTECTION | ALPHA BIOPESTICIDES LTD (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2026-04-09 | — | — | US | claimed |
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | UNIV INDIANA TRUSTEES (US) | 2026-03-19 | — | — | US | claimed |
| WO-2026044024-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF AMYLIN ANALOG, AND USES THEREOF | I2O THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4679085-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| US-20250258159-A1 | DEVICE, METHOD AND SYSTEM FOR MONITORING IMMUNE SYSTEM RESPONSE | Olaris, Inc. | 2025-08-14 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-1129220-A | Novel crystalline cephem acid addition salts and processes for their preparation | HOECHST AG (DE) | 1996-08-21 | — | — | CN | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0428080-A2 | Detection of appendicitis by measurement of ortho-hydroxyhippuric acid | APPENDITECH INC. (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0225189-A2 | Targeted enteral delivery system | R.P. SCHERER CORPORATION (US) | 1987-06-10 | — | — | EP | claimed |
| EP-0031561-B1 | A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1985-04-10 | — | — | EP | claimed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | HLA-DRB1, MICA, FTH1 | HPGD 2179/4885HTT 1541/4885HSD17B10 342/4885 |
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | FGF23, FGB, SFRP1 | HPGD 3565/4885HTT 4594/4885HSD17B10 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.